Diabetes mellitus has become a serious and chronic metabolic disorder that results from a
complex interaction of genetic and environmental factors, principally characterized by …

Obesity is a chronic disease associated with many complications. Weight loss of 5–15% can
improve many obesity-related complications. Despite the benefits of weight reduction, there …

Background Obesity is a major risk factor for many leading causes of illness and death
worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon …

The gut microbiota, which includes Akkermansia muciniphila, is known to modulate energy
metabolism, glucose tolerance, immune system maturation and function in humans …

Background Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor
agonist, is in development for type 2 diabetes and obesity. We assessed the efficacy and …

Growth differentiation factor 15 (GDF15) is a cytokine best known for affecting systemic
energy metabolism through its anorectic action. GDF15 expression and secretion from …

Aim To assess the efficacy and tolerability of tirzepatide treatment using three different dose‐
escalation regimens in patients with type 2 diabetes. Materials and Methods In this double …

Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly
improved clinical effects on glycemic control. However, real-world data concerning the …

The growing disease burden of diabetes mellitus is an important public health concern,
affecting over 400 million people globally. This epidemic, if not controlled in time, leads to …

Abstract Glucagon-like peptide 1 (GLP-1) agonists are a drug class used for the treatment of
diabetes that have recently gained FDA approval for medical management of obesity. The …